Shuttle Pharmaceuticals
SHPH
Market cap $3.3M

1.12 USD

+0.01

0.90%

At close Oct 11, 4:00 PM EDT

1 day

0.90%

5 days

-5.88%

1 month

-22.22%

3 months

-66.77%

6 months

-66.86%

Year to date

-72.28%

1 year

-76.42%

5 years

-99.64%

About: Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.

Employees: 8

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

29% more capital invested

Capital invested by funds: $26.8K [Q1] → $34.6K (+$7.81K) [Q2]

0.12% more ownership

Funds ownership: 0.39% [Q1] → 0.52% (+0.12%) [Q2]

14% less funds holding

Funds holding: 7 [Q1] → 6 (-1) [Q2]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for SHPH.

See Analyst Rankings

Financial journalist opinion

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Four of the planned six trial sites are now prepared to enroll patients in the clinical trial, including the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN) Cancer Institute, and Miami Cancer Institute, part of Baptist Health South Florida.

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024.

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today reports that it received formal notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Q2 Quarterly Report”).

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two of the six site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Site initiation visits have been completed for two sites. The trial is now open to enroll patients in the clinical trial.

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC).

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Shuttle Pharma Provides First Quarter 2024 Corporate Update

GAITHERSBURG, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024.

Shuttle Pharma Provides First Quarter 2024 Corporate Update

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

GAITHERSBURG, Md., April 23, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will present at the Planet MicroCap Showcase: VEGAS 2024, on Wednesday, May 1, 2024 at 4:30pm PT. The Company will also host in person one-on-one meetings with investors on Thursday, May 2, 2024.

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

GAITHERSBURG, Md., April 03, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference.

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

See News Rankings

Charts implemented using Lightweight Charts™